- Home
- GCMG vs VSTM Comparison
GCMG vs VSTM Comparison
Compare GCMG & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCMG
- VSTM
- Stock Information
- Founded
- GCMG 1971
- VSTM 2010
- Country
- GCMG United States
- VSTM United States
- Employees
- GCMG N/A
- VSTM N/A
- Industry
- GCMG Finance/Investors Services
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- GCMG Finance
- VSTM Health Care
- Exchange
- GCMG Nasdaq
- VSTM Nasdaq
- Market Cap
- GCMG 631.4M
- VSTM 598.2M
- IPO Year
- GCMG N/A
- VSTM 2012
- Fundamental
- Price
- GCMG $11.73
- VSTM $8.93
- Analyst Decision
- GCMG Buy
- VSTM Strong Buy
- Analyst Count
- GCMG 4
- VSTM 9
- Target Price
- GCMG $15.13
- VSTM $13.38
- AVG Volume (30 Days)
- GCMG 706.9K
- VSTM 1.7M
- Earning Date
- GCMG 11-07-2025
- VSTM 11-05-2025
- Dividend Yield
- GCMG 3.74%
- VSTM N/A
- EPS Growth
- GCMG N/A
- VSTM N/A
- EPS
- GCMG 0.19
- VSTM N/A
- Revenue
- GCMG $533,097,999.00
- VSTM $2,137,000.00
- Revenue This Year
- GCMG $4.88
- VSTM $88.50
- Revenue Next Year
- GCMG $11.78
- VSTM $398.66
- P/E Ratio
- GCMG $63.32
- VSTM N/A
- Revenue Growth
- GCMG 15.56
- VSTM N/A
- 52 Week Low
- GCMG $10.91
- VSTM $2.54
- 52 Week High
- GCMG $14.48
- VSTM $11.25
- Technical
- Relative Strength Index (RSI)
- GCMG 32.59
- VSTM 53.66
- Support Level
- GCMG $11.67
- VSTM $8.49
- Resistance Level
- GCMG $12.03
- VSTM $9.26
- Average True Range (ATR)
- GCMG 0.26
- VSTM 0.44
- MACD
- GCMG -0.11
- VSTM -0.12
- Stochastic Oscillator
- GCMG 4.82
- VSTM 50.59
About GCMG GCM Grosvenor Inc.
GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG and absolute return strategies. Company invest maximum in Private Equity. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.